

The first report on population-based data on characteristics, treatment and survival on Swedish myeloma patients diagnosed from 2008 through 2016



Swedish Myeloma Registry



4904 Multiple myeloma patients diagnosed between 2008-2016

3988 81.3% Multiple myeloma (MM)

916 18.6% Smoldering multiple myeloma (SMM)

Median age: 71 years ♂ 70 years ♀ 72 years



Median time of follow-up: 4.9 years

Survival rate in all myeloma patients

1-year SR

1973-1982	0.69 (95% CI:0.67-0.70)
1983-1992	0.74 (95% CI:0.73-0.75)
1993-2002	0.77 (95% CI:0.76-0.78)
2003-2013	0.82 (95% CI:0.81-0.83)

Median relative survival in MM

7.7 years for patients ≤ 65 years
3.4 years for patients ≥ 66 years

Treatment in all myeloma patients

- High-dose therapy with ASCT → 77% patients ≤ 66 years, 22% patients = 66-70 years
- Allogeneic transplantation → 1% patients
- Bisphosphonates → 79% patients ≤ 65 years
- Bortezomib, thalidomide, and/or lenalidomide → 31% patients in 2008→ 81% patients in 2014